These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
293 related items for PubMed ID: 9513601
1. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives. Cappelli A, Anzini M, Vomero S, Mennuni L, Makovec F, Doucet E, Hamon M, Bruni G, Romeo MR, Menziani MC, De Benedetti PG, Langer T. J Med Chem; 1998 Feb 26; 41(5):728-41. PubMed ID: 9513601 [Abstract] [Full Text] [Related]
2. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors. Cappelli A, Anzini M, Vomero S, Canullo L, Mennuni L, Makovec F, Doucet E, Hamon M, Menziani MC, De Benedetti PG, Bruni G, Romeo MR, Giorgi G, Donati A. J Med Chem; 1999 May 06; 42(9):1556-75. PubMed ID: 10229626 [Abstract] [Full Text] [Related]
3. Structure-affinity relationship studies on arylpiperazine derivatives related to quipazine as serotonin transporter ligands. Molecular basis of the selectivity SERT/5HT3 receptor. Cappelli A, Giuliani G, Gallelli A, Valenti S, Anzini M, Mennuni L, Makovec F, Cupello A, Vomero S. Bioorg Med Chem; 2005 May 16; 13(10):3455-60. PubMed ID: 15848758 [Abstract] [Full Text] [Related]
4. Further studies on the interaction of the 5-hydroxytryptamine3 (5-HT3) receptor with arylpiperazine ligands. development of a new 5-HT3 receptor ligand showing potent acetylcholinesterase inhibitory properties. Cappelli A, Gallelli A, Manini M, Anzini M, Mennuni L, Makovec F, Menziani MC, Alcaro S, Ortuso F, Vomero S. J Med Chem; 2005 May 19; 48(10):3564-75. PubMed ID: 15887964 [Abstract] [Full Text] [Related]
5. Synthesis and 5-HT3 receptor affinity of new quinolinecarboxylic acid derivatives. Orjales A, Alonso-Cires L, López-Tudanca PL, Tapia I, Labeaga L, Mosquera R. Drug Des Discov; 2000 May 19; 16(4):271-9. PubMed ID: 10807033 [Abstract] [Full Text] [Related]
6. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives. Tapia I, Alonso-Cires L, López-Tudanca PL, Mosquera R, Labeaga L, Innerárity A, Orjales A. J Med Chem; 1999 Jul 29; 42(15):2870-80. PubMed ID: 10425096 [Abstract] [Full Text] [Related]
7. Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding. Heidempergher F, Pillan A, Pinciroli V, Vaghi F, Arrigoni C, Bolis G, Caccia C, Dho L, McArthur R, Varasi M. J Med Chem; 1997 Oct 10; 40(21):3369-80. PubMed ID: 9341912 [Abstract] [Full Text] [Related]
8. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity. Hirokawa Y, Fujiwara I, Suzuki K, Harada H, Yoshikawa T, Yoshida N, Kato S. J Med Chem; 2003 Feb 27; 46(5):702-15. PubMed ID: 12593651 [Abstract] [Full Text] [Related]
9. Discrimination in 5-HT(3) receptor binding in murine brain and cultured cell preparations. Zhang ZJ, Trivedi BL, de Paulis T, Schmidt DE, Hewlett WA. Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb 27; 365(2):123-32. PubMed ID: 11819030 [Abstract] [Full Text] [Related]
10. Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents. Leopoldo M, Berardi F, Colabufo NA, Contino M, Lacivita E, Niso M, Perrone R, Tortorella V. J Med Chem; 2004 Dec 16; 47(26):6616-24. PubMed ID: 15588097 [Abstract] [Full Text] [Related]
11. Characteristics of [14C]guanidinium accumulation in NG 108-15 cells exposed to serotonin 5-HT3 receptor ligands and substance P. Emerit MB, Riad M, Fattaccini CM, Hamon M. J Neurochem; 1993 Jun 16; 60(6):2059-67. PubMed ID: 7684066 [Abstract] [Full Text] [Related]
12. Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure. Campiani G, Cappelli A, Nacci V, Anzini M, Vomero S, Hamon M, Cagnotto A, Fracasso C, Uboldi C, Caccia S, Consolo S, Mennini T. J Med Chem; 1997 Oct 24; 40(22):3670-8. PubMed ID: 9357534 [Abstract] [Full Text] [Related]
13. Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut. Sato Y, Yamada M, Yoshida S, Soneda T, Ishikawa M, Nizato T, Suzuki K, Konno F. J Med Chem; 1998 Jul 30; 41(16):3015-21. PubMed ID: 9685241 [Abstract] [Full Text] [Related]
14. Benzimidazole derivatives. Part 5: design and synthesis of new benzimidazole-arylpiperazine derivatives acting as mixed 5-HT1A/5-HT3 ligands. López-Rodríguez ML, Benhamú B, Morcillo MJ, Tejada I, Avila D, Marco I, Schiapparelli L, Frechilla D, Del Río J. Bioorg Med Chem; 2004 Oct 01; 12(19):5181-91. PubMed ID: 15351401 [Abstract] [Full Text] [Related]
15. Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT3 serotonin receptors. Dukat M, Abdel-Rahman AA, Ismaiel AM, Ingher S, Teitler M, Gyermek L, Glennon RA. J Med Chem; 1996 Sep 27; 39(20):4017-26. PubMed ID: 8831767 [Abstract] [Full Text] [Related]
16. New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation. Jurczyk S, Kołaczkowski M, Maryniak E, Zajdel P, Pawłowski M, Tatarczyńska E, Kłodzińska A, Chojnacka-Wójcik E, Bojarski AJ, Charakchieva-Minol S, Duszyńska B, Nowak G, Maciag D. J Med Chem; 2004 May 06; 47(10):2659-66. PubMed ID: 15115407 [Abstract] [Full Text] [Related]
17. Novel and selective partial agonists of 5-HT3 receptors. 2. Synthesis and biological evaluation of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines. Prunier H, Rault S, Lancelot JC, Robba M, Renard P, Delagrange P, Pfeiffer B, Caignard DH, Misslin R, Guardiola-Lemaitre B, Hamon M. J Med Chem; 1997 Jun 06; 40(12):1808-19. PubMed ID: 9191957 [Abstract] [Full Text] [Related]
18. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. Campiani G, Butini S, Trotta F, Fattorusso C, Catalanotti B, Aiello F, Gemma S, Nacci V, Novellino E, Stark JA, Cagnotto A, Fumagalli E, Carnovali F, Cervo L, Mennini T. J Med Chem; 2003 Aug 28; 46(18):3822-39. PubMed ID: 12930145 [Abstract] [Full Text] [Related]
19. Biguanide derivatives: agonist pharmacology at 5-hydroxytryptamine type 3 receptors in vitro. Morain P, Abraham C, Portevin B, De Nanteuil G. Mol Pharmacol; 1994 Oct 28; 46(4):732-42. PubMed ID: 7969053 [Abstract] [Full Text] [Related]
20. 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. Jorand-Lebrun C, Pauwels PJ, Palmier C, Moret C, Chopin P, Perez M, Marien M, Halazy S. J Med Chem; 1997 Nov 21; 40(24):3974-8. PubMed ID: 9397179 [Abstract] [Full Text] [Related] Page: [Next] [New Search]